Citigroup
PBYI icon

Citigroup’s Puma Biotechnology PBYI Stock Holding History

Citigroup’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-61,800
Closed -$634K – 7100
2020
Q4 		$634K Sell
61,800
-5,200
-8% -$52.7K ﹤0.01% 3993
2020
Q3 		$676K Sell
67,000
-57,100
-46% -$581K ﹤0.01% 3592
2020
Q2 		$1.29M Sell
124,100
-2,700
-2% -$27.9K ﹤0.01% 3278
2020
Q1 		$1.07M Sell
126,800
-32,200
-20% -$313K ﹤0.01% 3102
2019
Q4 		$1.39M Buy
159,000
+58,600
+58% +$485K ﹤0.01% 3384
2019
Q3 		$1.08M Buy
100,400
+70,100
+231% +$757K ﹤0.01% 3555
2019
Q2 		$385K Buy
30,300
+12,600
+71% +$290K ﹤0.01% 4678
2019
Q1 		$687K Sell
17,700
-18,800
-52% -$574K ﹤0.01% 3824
2018
Q4 		$743K Buy
36,500
+25,900
+244% +$777K ﹤0.01% 3702
2018
Q3 		$486K Sell
10,600
-2,700
-20% -$130K ﹤0.01% 4313
2018
Q2 		$787K Buy
13,300
+8,300
+166% +$481K ﹤0.01% 3615
2018
Q1 		$340K Sell
5,000
-16,600
-77% -$1.24M ﹤0.01% 4396
2017
Q4 		$2.13M Buy
21,600
+200
+0.9% +$22.4K ﹤0.01% 2609
2017
Q3 		$2.56M Sell
21,400
-3,700
-15% -$344K ﹤0.01% 2400
2017
Q2 		$2.19M Buy
25,100
+12,900
+106% +$722K ﹤0.01% 2495
2017
Q1 		$454K Sell
12,200
-10,100
-45% -$369K ﹤0.01% 3950
2016
Q4 		$685K Buy
22,300
+12,900
+137% +$558K ﹤0.01% 4053
2016
Q3 		$630K Buy
9,400
+7,200
+327% +$364K ﹤0.01% 3681
2016
Q2 		$66K Sell
2,200
-2,000
-48% -$62.5K ﹤0.01% 5392
2016
Q1 		$123K Sell
4,200
-13,500
-76% -$610K ﹤0.01% 5514
2015
Q4 		$1.39M Buy
17,700
+14,000
+378% +$1.1M ﹤0.01% 2789
2015
Q3 		$279K Buy
+3,700
New +$350K ﹤0.01% 4249

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Citigroup's PBYI Position: Q1 2026 in Review

Citigroup increased its Puma Biotechnology (PBYI) stake by 44% in Q1 2026, buying an estimated $6.72K and bringing the position to 3,422 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4795.

Citigroup first reported a position in PBYI in Q3 2013 and has held it in 49 quarters since. The position peaked at $6.77M in Q4 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Citigroup held 3,422 shares of Puma Biotechnology worth $21.9K as of Q1 2026.
  • Citigroup bought 1,042 Puma Biotechnology shares in Q1 2026, an estimated $6.72K.
  • Puma Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4795 holding.
  • Citigroup first reported a position in Puma Biotechnology in Q3 2013 and has held it in 49 quarters since.
  • Citigroup's Puma Biotechnology position peaked at $6.77M in Q4 2017.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.